today announced positive top-line results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring the BRAFV600
evaluating הגייה עם משמעויות, מילים נרדפות, הפכים, תרגומים, משפטים ועוד